Company news
Minerva Neurosciences, Inc (NASDAQ:NERV) news
Minerva Neurosciences, Inc news releases on 6ix. Latest, Aug 2, 2021: Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
Press releases — page 2
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
August 1, 2021
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
May 11, 2021
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension
May 10, 2021
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
March 7, 2021
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
February 28, 2021
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
January 18, 2021
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
November 30, 2020
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
November 1, 2020
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
October 25, 2020
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
August 2, 2020
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
June 30, 2020
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 31, 2020
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 28, 2020
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
May 3, 2020
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
March 8, 2020
Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
March 1, 2020
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
February 4, 2020
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
January 5, 2020
Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
December 17, 2019
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
November 3, 2019
Minerva Neurosciences Announces Update for Three Clinical Trials
September 30, 2019
Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
September 25, 2019